Shopping Cart 0
Cart Subtotal
AED 0

Egalet Corp (EGLT) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

Egalet Corp (EGLT)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Egalet Corp (Egalet), formerly Zyla Life Sciences, is a commercial-stage pharmaceutical company that commercializes innovative treatment options for inflammation and various types of pain. The company offers branded non-narcotic, nonsteroidal, and anti-inflammatory drugs and formulations including ketorolac tromethamine nasal spray, diclofenac, indomethacin, oxycodone HCI, USP, and meloxicam. Its acute and chronic pain products enable healthcare providers to address the issue of prescription abuse. The company harnesses its proprietary Guardian technology, a polymer matrix tablet technology, for advancing its pipeline products. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp Key Recent Developments

Jun 19,2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors

Jun 12,2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer

May 16,2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences

Nov 19,2018: Egalet announces third quarter 2018 financial results

Aug 08,2018: Egalet reports second quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Egalet Corp-Key Facts

Egalet Corp-Key Employees

Egalet Corp-Key Employee Biographies

Egalet Corp-Major Products and Services

Egalet Corp-History

Egalet Corp-Company Statement

Egalet Corp-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Egalet Corp-Business Description

Product Category: Arymo ER

Performance

Product Category: Oxaydo

Performance

Product Category: Sprix Nasal Spray

Performance

R&D Overview

Egalet Corp-Corporate Strategy

Egalet Corp-SWOT Analysis

SWOT Analysis-Overview

Egalet Corp-Strengths

Egalet Corp-Weaknesses

Egalet Corp-Opportunities

Egalet Corp-Threats

Egalet Corp-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Egalet Corp, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 19, 2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors

Jun 12, 2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer

May 16, 2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences

Nov 19, 2018: Egalet announces third quarter 2018 financial results

Aug 08, 2018: Egalet reports second quarter 2018 financial results

Jun 07, 2018: Egalet Names John Varian Board Director

May 08, 2018: Egalet Reports First Quarter 2018 Financial Results

Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Egalet Corp, Performance Chart (2014-2018)

Egalet Corp, Ratio Charts

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Egalet Corp, Key Facts

Egalet Corp, Key Employees

Egalet Corp, Key Employee Biographies

Egalet Corp, Major Products and Services

Egalet Corp, History

Egalet Corp, Other Locations

Egalet Corp, Subsidiaries

Egalet Corp, Key Competitors

Egalet Corp, Ratios based on current share price

Egalet Corp, Annual Ratios

Egalet Corp, Annual Ratios (Cont...1)

Egalet Corp, Interim Ratios

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Egalet Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Egalet Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Teva Pharmaceutical Industries, Ltd.-Portfolio of Generic Products-US

Pfizer Consumer Healthcare

Nektar Therapeutics

Mallinckrodt LLC

Endo Pharmaceuticals Inc

Actavis LLC

Company Profile

Company Profile Title

Egalet Corp (EGLT)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Egalet Corp (Egalet), formerly Zyla Life Sciences, is a commercial-stage pharmaceutical company that commercializes innovative treatment options for inflammation and various types of pain. The company offers branded non-narcotic, nonsteroidal, and anti-inflammatory drugs and formulations including ketorolac tromethamine nasal spray, diclofenac, indomethacin, oxycodone HCI, USP, and meloxicam. Its acute and chronic pain products enable healthcare providers to address the issue of prescription abuse. The company harnesses its proprietary Guardian technology, a polymer matrix tablet technology, for advancing its pipeline products. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp Key Recent Developments

Jun 19,2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors

Jun 12,2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer

May 16,2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences

Nov 19,2018: Egalet announces third quarter 2018 financial results

Aug 08,2018: Egalet reports second quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Egalet Corp-Key Facts

Egalet Corp-Key Employees

Egalet Corp-Key Employee Biographies

Egalet Corp-Major Products and Services

Egalet Corp-History

Egalet Corp-Company Statement

Egalet Corp-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Egalet Corp-Business Description

Product Category: Arymo ER

Performance

Product Category: Oxaydo

Performance

Product Category: Sprix Nasal Spray

Performance

R&D Overview

Egalet Corp-Corporate Strategy

Egalet Corp-SWOT Analysis

SWOT Analysis-Overview

Egalet Corp-Strengths

Egalet Corp-Weaknesses

Egalet Corp-Opportunities

Egalet Corp-Threats

Egalet Corp-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Egalet Corp, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 19, 2019: Zyla Life Sciences appoints Dr. Gary M. Phillips to board of directors

Jun 12, 2019: Zyla Life Sciences appoints Dr. H. Jeffrey Wilkins as chief medical officer

May 16, 2019: Egalet reports first quarter 2019 financial results and plan to change company name to Zyla Life Sciences

Nov 19, 2018: Egalet announces third quarter 2018 financial results

Aug 08, 2018: Egalet reports second quarter 2018 financial results

Jun 07, 2018: Egalet Names John Varian Board Director

May 08, 2018: Egalet Reports First Quarter 2018 Financial Results

Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Egalet Corp, Performance Chart (2014-2018)

Egalet Corp, Ratio Charts

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Egalet Corp, Key Facts

Egalet Corp, Key Employees

Egalet Corp, Key Employee Biographies

Egalet Corp, Major Products and Services

Egalet Corp, History

Egalet Corp, Other Locations

Egalet Corp, Subsidiaries

Egalet Corp, Key Competitors

Egalet Corp, Ratios based on current share price

Egalet Corp, Annual Ratios

Egalet Corp, Annual Ratios (Cont...1)

Egalet Corp, Interim Ratios

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Egalet Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Egalet Corp, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Teva Pharmaceutical Industries, Ltd.-Portfolio of Generic Products-US

Pfizer Consumer Healthcare

Nektar Therapeutics

Mallinckrodt LLC

Endo Pharmaceuticals Inc

Actavis LLC